Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE)

Accepted/In Press date: 15 January 2021

e-pub ahead of print date: 20 January 2021

Published date: 1 April 2021

Additional Information: Funding Information: S.J. Crabb reported grants and nonfinancial support from Astex Pharmaceuticals during the conduct of the study, personal fees and nonfinancial support from MSD, Bayer, Roche, and Janssen Cilag, personal fees from Astellas, Pfizer, and BeiGene, grants and personal fees from AstraZeneca, and grants from Clovis Oncology outside the submitted work. S. Danson reported grants from Cancer Research UK & the Department of Health and NIHR during the conduct of the study. J.W.F. Catto reported personal fees from AstraZeneca, Roche, Janssen, BMS, Ferring, Nucleix, and MAD during the conduct of the study. S. Hussain reported personal fees from AstraZeneca, Roche, Merck, Janssen, BMS, GlaxoSmithKline, Pfizer, Eisai, and Pierre Fabre outside the submitted work. D. Dunkley reported grants from Astex Pharmaceuticals during the conduct of the study. N. Downs reported grants from Astex Pharmaceuticals during the conduct of the study. E. Marwood reported grants and nonfinancial support from Astex Pharmaceuticals during the conduct of the study. L. Day reported grants from Astex Pharmaceuticals during the conduct of the study. D. Ellis reported grants from Astex Pharmaceuticals during the conduct of the study. A. Birtle reported other from Janssen, Roche, and MSD outside the submitted work. R. Huddart reported grants from Astex Pharmaceuticals during the conduct of the study, grants, personal fees, and nonfinancial support from MSD and Roche, personal fees and nonfinancial support from Janssen and Nektar Pharmaceuticals, and personal fees from Bayer and Astellas outside the submitted work, and is a partner in Cancer Centre London. G. Griffiths reported grants from AstraZeneca and personal fees from AstraZeneca during the conduct of the study, grants from Janssen Cilag, AstraZeneca, Novartis, Astex Pharmaceuticals, Roche, Heartflow, BMS, and BioNTech and personal fees from Celldex outside the submitted work. No disclosures were reported by the other authors. Funding Information: We thank the patients and their families for participating in this study, along with all investigators and site personnel. We thank Cancer Research UK and Astex Pharmaceuticals for provision of research funding to undertake this trial. The authors also wish to acknowledge Prof. John Staffurth, Dr. Anthony Kong, and Jacqueline Birks as members of the independent data monitoring and ethicscommittee. R.Huddart and B. Johnson acknowledge the support of the Institute of Cancer Research/Royal Marsden FT NIHR Biomedical Research Centre. This work was supported by Cancer Research UK (grant No. C9317/A19903) and Astex Pharmaceuticals. Publisher Copyright: © 2021 American Association for Cancer Research.

Local EPrints ID: 447027

URI: http://eprints.soton.ac.uk/id/eprint/447027

DOI: doi:10.1158/1078-0432.CCR-20-3946

ISSN: 1078-0432

PURE UUID: b887f25d-18e8-42ef-a160-eb9fd00dccca

ORCID for Simon J Crabb: orcid.org/0000-0003-3521-9064

ORCID for Gareth Griffiths: orcid.org/0000-0002-9579-8021

Date deposited: 02 Mar 2021 17:30

Last modified: 17 Mar 2024 06:20